JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 245 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tyrphostin AG 490
CAS:Formula:C17H14N2O3Purity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:294.31N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Formula:C9H20N2Purity:98.05% - 98.82%Color and Shape:Pale Yellow Clear LiquidMolecular weight:156.2685Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Formula:C25H31N9O2Purity:98.87% - 99.88%Color and Shape:SolidMolecular weight:489.57Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C21H21ClFN7Purity:99.55%Color and Shape:SolidMolecular weight:425.89Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C25H24FN7O4Purity:99.74% - 99.82%Color and Shape:SolidMolecular weight:505.5Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Formula:C25H29F2N7O4SPurity:99.82% - 99.97%Color and Shape:SolidMolecular weight:561.6TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Formula:C28H32N4O3SPurity:99.02% - 99.59%Color and Shape:SolidMolecular weight:504.64Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Formula:C16H18N6OPurity:99.95%Color and Shape:SolidMolecular weight:310.35Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Formula:C24H28N8O2Purity:98.06% - 99.94%Color and Shape:SolidMolecular weight:460.53Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Formula:C21H20FN7Purity:98.4% - 99.01%Color and Shape:SolidMolecular weight:389.43WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Formula:C13H8Cl2N2O2SPurity:99.69%Color and Shape:SoildMolecular weight:327.19Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Formula:C25H26F2N6O2Purity:98.71%Color and Shape:SoildMolecular weight:480.51JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Formula:C23H24N2OPurity:98.36% - 99.15%Color and Shape:SolidMolecular weight:344.45(E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide
CAS:Formula:C17H14N2O3Purity:98%Color and Shape:SolidMolecular weight:294.3047Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Formula:C23H25F5N7O5PPurity:99.57%Color and Shape:SolidMolecular weight:605.45JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Formula:C30H32N8O5SColor and Shape:SolidMolecular weight:616.69JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Formula:C17H14ClN5O2Purity:98%Color and Shape:SolidMolecular weight:355.78MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Formula:C23H26N4O2SColor and Shape:SolidMolecular weight:422.54TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Color and Shape:SolidMolecular weight:404.16485SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Formula:C36H36N10O5Color and Shape:SolidMolecular weight:688.74DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Formula:C25H38N4O3Color and Shape:SolidMolecular weight:442.59JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColor and Shape:SolidMolecular weight:442.51SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Formula:C43H45N13O9SPurity:98%Color and Shape:SolidMolecular weight:919.96Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Formula:C17H18N6Color and Shape:SolidMolecular weight:314.41Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Formula:C63H107N19O20S2Purity:98%Color and Shape:SolidMolecular weight:1514.77TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Color and Shape:Odour SolidJAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Formula:C33H33D3FN9O2Color and Shape:SolidMolecular weight:612.71Tyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Formula:C16H16ClN5O2Color and Shape:SolidMolecular weight:345.78JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Formula:C14H10ClN3OS2Purity:99.64%Color and Shape:SolidMolecular weight:335.83JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Formula:C15H12Cl2N2O4SPurity:98.01%Color and Shape:SolidMolecular weight:387.24HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Formula:C60H69N17O11SColor and Shape:SolidMolecular weight:1236.36Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Formula:C17H20N8O2SPurity:99.94%Color and Shape:SoildMolecular weight:400.46JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Color and Shape:Odour SolidPROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Formula:C55H69N13O7SPurity:98%Color and Shape:SolidMolecular weight:1056.28AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Formula:C18H19N5OColor and Shape:SolidMolecular weight:321.38LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Formula:C29H31F3N6O2SColor and Shape:SolidMolecular weight:584.66Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Formula:C88H138N20O34P2Purity:98%Color and Shape:SolidMolecular weight:2082.1SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Formula:C41H46N12O5SColor and Shape:SolidMolecular weight:818.95JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Formula:C20H12ClN3OColor and Shape:SolidMolecular weight:345.79JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Color and Shape:Odour SolidTyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Color and Shape:Odour SolidJAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formula:C18H20F3N7OColor and Shape:SolidMolecular weight:407.401SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Formula:C42H43N13O7SColor and Shape:SolidMolecular weight:873.94Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Color and Shape:Odour SolidFDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Color and Shape:LiquidWDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formula:C29H31F3N4O4Color and Shape:SolidMolecular weight:556.576S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Formula:C17H18N6Purity:98%Color and Shape:SolidMolecular weight:306.37JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Purity:98%Color and Shape:Odour Solid
